NL-OMON24009招募中不适用
A first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate CIT-013 in healthy volunteers with and without an intravenous lipopolysaccharide challenge
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Citryll BV
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy men or women of non-child bearing potential (WNCBP), 18 to 55 years of age (inclusive) at screening. The health status is verified by absence of evidence of any clinically significant active or uncontrolled chronic disease following a detailed medical history, a complete physical examination including vital signs, laboratory measurements, and 12-lead ECG;
- •2. Signed informed consent, able and willing to comply with the requirements of the study protocol.
- •3. Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and a body weight between 50 and 150 kg, inclusive at screening.
- •4. All male volunteers must practice effective contraception during the study and be willing and able to continue contraception for at least 90 days after their last dose of study treatment.
- •5. Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions.
排除标准
- •1.Any confirmed or suspected disease or condition associated with immune system impairment, including autoimmune diseases, HIV, asplenia or recurrent severe infections.
- •2.Use of chronic (more than 14 days) immunosuppressant or immunomodulatory drugs within the 3 months prior to IMP administration, or isolated (non-chronic) use within 30 days prior to IMP administration.
- •3.Subject has an active, uncontrolled acute or chronic systemic fungal, bacterial, and/or viral, infection within the past 30 days.
- •4.Subjects with evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases.
- •5.Subject has a positive SARS-CoV-2 PCR based test within 72 hours of receiving CIT-013.
- •6.Use of prescription or over-the-counter (OTC) drugs, vitamins, minerals and dietary supplements, within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication until EOS. Herbal supplements
- •7.and hormone replacement therapy must be discontinued 30 days prior to the first dose of study medication until EOS. Excluded from this list is paracetamol at doses of <4 g/day on all study days except day 1 of part B.
- •8.Exceptions will only be made if the rationale is clearly documented by the investigator.
- •9.Receipt of live or attenuated vaccine 90 days prior to first study intervention administration.
- •10.Vaccination (completion of 2nd vaccination shot if applicable) against SARS-CoV-2 or influenza vaccinations less than 14 days prior to first study drug administration.
- •11.Known hypersensitivity to any of the constituents or excipients of CIT-013 or history of relevant drug and/or food allergy (anaphylactic, anaphylactoid reactions).
- •12.Smoking > than 10 cigarettes (or equivalent) per week and/or using nicotine-based products within 1 month prior to CIT-013 administration and/or unwillingness to abstain from the use of these from screening until EOS.
- •13.Extreme exercise (e.g. marathon or triathlon) within 2 weeks of screening.
- •14.Subject has participated in an intravenous LPS challenge study before (Part B).
研究者
相似试验
已完成
不适用
A first-in-human, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics (including food effect), pharmacodynamics and proof of concept of CKD-506 in healthy subjects and inflammatory bowel disease patientsinflammatory bowel disease1001796910023213rheumatoid arthritisNL-OMON45538Chong Kun Dang Pharmaceutical Corp.80
已完成
不适用
A first-in-human, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to investigate the safety, tolerablility, pharmacokinetics (including food and gender effect), and pharmacodynamics of LNP1955 in healthy subjects.Inflammatory disease conditionsrheumatoid arthritis.10003816NL-OMON42416upin Limited66
已完成
不适用
A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of INS-3001 in healthy subjects and patients with moderate aortic valve stenosisNL-OMON52051Vifor (International) Inc.30
已完成
不适用
A first-in-human, randomized, double-blind, placebo-controlled, study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of GLPG4059 in adult, healthy, male subjects.NL-OMON55090Galapagos NV57
招募中
不适用
A first-in-human, randomized, double-blind, placebo-controlled study to evaluate, single ascending doses of CIT-013 in healthy volunteers with and without an intravenous lipopolysaccharide challenge and repeat dosing in healthy volunteers and patients with Rheumatoid Arthritis.NL-OMON56333Citryll84